close

Fenwick Represents DexCom in Acquisition of Sweetspot

March 09, 2012

Fenwick & West LLP represented DexCom (NASDAQ: DXCM), a leader in continuous glucose sensing technologies in its acquisition of SweetSpot Diabetes Care, Inc., a healthcare-focused information technology company, in an all stock transaction, with initial consideration of up to $4.5 million and performance milestone-based earnout consideration of up to an additional $4 million.

The Fenwick transaction team included corporate attorneys Robert Freedman, David Michaels, Michael Brown, Aaron Hou, and Adam Andrews; executive compensation and employee benefits attorney Blake Martell; licensing attorney Lisa Kenkel; and tax attorney Will Skinner.

More information about the transaction is available on the official announcement from DexCom.​